Cervical Cancer

New guidelines issued by the US Preventive Services Task Force (USPSTF) recommend for women aged 30 to 65 years at average risk for cervical cancer to choose to receive a Pap smear alone every 3 years, screening with the high-risk human papillomavirus test alone, or cotesting every 5 years.

The FDA announced today that it has approved the first biosimilar for the treatment of multiple types of cancer.

Pelvic IMRT causes less GI, GU toxicities than standard pelvic radiation therapy for patients with gynecologic cancers.

Canadian researchers led by Salaheddin M. Mahmud, MD, PhD of the University of Manitoba conducted a study to assess the effectiveness of the quadrivalent human papillomavirus (QHPV) vaccine against cervical dysplasia.

Women are now advised to have fewer screenings over their lifetime.